Benzinga··Vandana SinghNovo Nordisk's Wegovy Pill Shows 17% Average Weight Loss in OASIS 4 Trial
Novo Nordisk's oral semaglutide achieved 17% average weight loss with superior efficacy versus competitors, positioning the GLP-1 pill as a market leader.
NVOclinical trialweight loss